Eli Lilly and Company (LLY) Holdings Lifted by Prudential PLC
Prudential PLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 37.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,453 shares of the company’s stock after purchasing an additional 42,579 shares during the quarter. Prudential PLC’s holdings in Eli Lilly and were worth $12,958,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Accredited Investors Inc. increased its stake in Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares in the last quarter. Northwest Quadrant Wealth Management LLC increased its stake in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after acquiring an additional 19 shares during the period. Oakworth Capital Inc. increased its stake in shares of Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the period. Sfmg LLC increased its stake in shares of Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the period. Finally, Jackson Grant Investment Advisers Inc. increased its stake in shares of Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 76.61% of the company’s stock.
Eli Lilly and Company (NYSE LLY) opened at $83.51 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The stock has a market cap of $91,589.09, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 1.84 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $64.18 and a twelve month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $0.88 earnings per share. equities research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 772,003 shares of company stock worth $64,837,441. Insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/22/eli-lilly-and-company-lly-holdings-lifted-by-prudential-plc.html.
A number of analysts have recently weighed in on LLY shares. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Piper Jaffray Companies reiterated a “buy” rating and issued a $103.00 price objective on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $89.97.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.